HIGH RISK MYELODYSPLASTIC SYNDROME
Clinical trials for HIGH RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HIGH RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for HIGH RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Shielding hearts from Chemo's toxic blow in blood cancer battle
Disease control Recruiting nowThis study is testing whether a drug called dexrazoxane can protect the heart from damage caused by powerful chemotherapy used to treat aggressive blood cancers like acute myeloid leukemia. It will enroll 100 patients with these cancers who are receiving a specific combination of…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug cocktail tested to fight aggressive blood cancers
Disease control Recruiting nowThis study is testing a combination of five drugs to treat adults newly diagnosed with specific, aggressive forms of blood cancer. The goal is to see if this combination is safe and effective at putting the cancer into remission. The treatment involves chemotherapy and a targeted…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for tough blood cancers: experimental combo targets leukemia survival
Disease control Recruiting nowThis study is testing whether adding a newer drug called venetoclax to a standard, strong chemotherapy regimen works better for adults with acute myeloid leukemia (AML). The goal is to see if this combination is safe, find the best dose, and measure how well it controls the cance…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Could removing metals from the body help fight leukemia?
Disease control Recruiting nowThis early-stage study is testing whether adding metal-detoxifying drugs to standard chemotherapy can help control acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to see if lowering metal levels in the blood and bone marrow improves treatment res…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New drug duo tested in fight against aggressive blood cancers
Disease control Recruiting nowThis study is testing a combination of two drugs, CPX-351 and quizartinib, to see if they can help control acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The main goals are to find the safest and most effective dose and to see how well the treatment wo…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New hope for tough blood cancers: Four-Drug attack trial opens
Disease control Recruiting nowThis trial is testing whether adding a newer targeted drug (quizartinib) to a standard three-drug chemotherapy cocktail works better for controlling aggressive blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It is for adults (18-65 fo…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New shot in the arm for leukemia patients Who've run out of options
Disease control Recruiting nowThis is the first study in people testing a new drug called CBX-250 for several types of advanced blood cancers that have come back or stopped responding to standard treatments. The main goal is to find a safe dose and see how well the body handles the drug, which is given as an …
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC